Besides the generation of an immunosuppressive TME, expression of activated epithelial Notch1 (Rosa26N1icd) drives poor prognosis subtypes CMS4 and CRIS-B; however, Notch1 activation in the context of Apc mutations (Apcfl/+) didn’t trigger a subtype switch and tumours remained non-metastatic CMS2/3 tumours [40••]. Here, NOTCH1 is linked to neoplasm.